BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29893346)

  • 41. Myeloid sarcoma of the vulva post-bone marrow transplant presenting as isolated extramedullary relapse in a patient with acute myeloid leukemia.
    Nazer A; Al-Badawi I; Chebbo W; Chaudhri N; El-Gohary G
    Hematol Oncol Stem Cell Ther; 2012; 5(2):118-21. PubMed ID: 22828376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
    Harousseau JL; Milpied N; Brière J; Desablens B; Ghandour C
    Nouv Rev Fr Hematol (1978); 1990; 32(4):227-30. PubMed ID: 2290708
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma.
    Shimizu H; Saitoh T; Tanaka M; Mori T; Sakura T; Kawai N; Kanda Y; Nakaseko C; Yano S; Fujita H; Fujisawa S; Miyawaki S; Kanamori H; Okamoto S
    Leukemia; 2012 Dec; 26(12):2469-73. PubMed ID: 22699453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast myeloid sarcoma after allogeneic stem cell transplantation for acute myelomonocytic leukemia - case report.
    Bubulac L; Bardaş A; Popa DC; Vasilache ED; Ionescu BO; Coriu D; Varady Z; Dobrea CM
    Rom J Morphol Embryol; 2019; 60(2):707-711. PubMed ID: 31658348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Granulocytic sarcoma with late transformation into acute myeloblastic leukemia--case report].
    Basa J; Wolska-Smoleń T; Walter Z; Skotnicki AB
    Przegl Lek; 2006; 63(8):706-10. PubMed ID: 17441389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
    Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA;
    Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Testicular myeloid sarcoma: a relapse of acute myeloid leukaemia after allogeneic peripheral blood stem cell transplantation- a rare presentation.
    Alam S; Palaniyandy V; Thirunavukkarasu C; Kumaresan N
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35304354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Ji L; Haider M; Pullarkat V
    Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
    Evensen SA; Brinch L; Wisløff F
    Tidsskr Nor Laegeforen; 1989 Jun; 109(19-21):2004-6. PubMed ID: 2749689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
    Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
    Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
    Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haploidentical peripheral blood stem cell infusion in combination with chemotherapy for acute myeloid leukaemia in elderly patients.
    Bishop DC; Johnston AJ; Kwan JM; Antonenas V; Gottlieb DJ
    Intern Med J; 2014 Oct; 44(10):1038-40. PubMed ID: 25302724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is there a "gold" standard treatment for patients with isolated myeloid sarcoma?
    Antic D; Elezovic I; Milic N; Suvajdzic N; Vidovic A; Perunicic M; Djunic I; Mitrovic M; Tomin D
    Biomed Pharmacother; 2013 Feb; 67(1):72-7. PubMed ID: 23218987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
    Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
    Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
    Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Krejci M; Doubek M; Dusek J; Brychtova Y; Racil Z; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
    Ann Hematol; 2013 Oct; 92(10):1397-403. PubMed ID: 23728608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
    Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
    Koren-Michowitz M; Maayan H; Apel A; Shem-Tov N; Yerushalmi R; Volchek Y; Avigdor A; Shimoni A; Nagler A
    Ann Hematol; 2015 Mar; 94(3):375-8. PubMed ID: 25307457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.